Geron
Geron
GERN
NASDAQ
4.75
USD
39.71%
About
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes.
It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 6.7M |
| Three Month Average Volume | 249.5M |
| High Low | |
| Fifty-Two Week High | 5.34 USD |
| Fifty-Two Week Low | 1.64 USD |
| Fifty-Two Week High Date | 12 Jun 2024 |
| Fifty-Two Week Low Date | 13 Mar 2024 |
| Price and Volume | |
| Current Price | 4.75 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -1.62% |
| Thirteen Week Relative Price Change | 25.02% |
| Twenty-Six Week Relative Price Change | 91.15% |
| Fifty-Two Week Relative Price Change | 56.00% |
| Year-to-Date Relative Price Change | 90.10% |
| Price Change | |
| One Day Price Change | 4.17% |
| Thirteen Week Price Change | 33.80% |
| Twenty-Six Week Price Change | 110.18% |
| Five Day Price Change | 4.63% |
| Fifty-Two Week Price Change | 95.47% |
| Year-to-Date Price Change | 125.12% |
| Month-to-Date Price Change | 0.21% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.45503 USD |
| Book Value Per Share (Most Recent Quarter) | 0.51027 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.45503 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.51027 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.37296 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00042 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00226 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.32266 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.35946 USD |
| Normalized (Last Fiscal Year) | -0.32266 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.32266 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.35946 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.32266 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.35946 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.61239 USD |
| Cash Per Share (Most Recent Quarter) | 0.6035 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.32189 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.3601 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.34305 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -17,130 |
| Cash Flow Revenue (Trailing Twelve Months) | -15,192 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -15,990.60% |
| Pretax Margin (Last Fiscal Year) | -77,690.72% |
| Pretax Margin (5 Year) | -19,949.13% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | 63.00% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -81,832.91% |
| Operating Margin (Trailing Twelve Months) | -16,559.94% |
| Operating Margin (5 Year) | -20,275.98% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -77,690.72% |
| Net Profit Margin (Trailing Twelve Months) | -15,990.60% |
| Net Profit Margin (5 Year) | -19,949.13% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -13.75% |
| Tangible Book Value (5 Year) | 6.89% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 2,941.38% |
| Revenue Growth (3 Year) | -25.97% |
| Revenue Change (Trailing Twelve Months) | 205.11% |
| Revenue Per Share Growth | -41.46% |
| Revenue Growth (5 Year) | -2.15% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 120.29% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -14.56% |
| EPS Change (Trailing Twelve Months) | 3.66% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 12 |
| Price to Tangible Book (Most Recent Quarter) | 9 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -279,298,000 |
| Net Debt (Last Fiscal Year) | -251,755,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 12.1K |
| Price to Sales (Trailing Twelve Months) | 2.1K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 10 |
| Price to Book (Most Recent Quarter) | 9 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 14 |
| Long Term Debt to Equity (Most Recent Quarter) | 12 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | 4 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -168,573,000 |
| Free Cash Flow (Trailing Twelve Months) | -208,585,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 33 |
| Total Debt to Equity (Most Recent Quarter) | 27 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -62.99% |
| Return on Assets (Trailing Twelve Months) | -50.78% |
| Return on Assets (5 Year) | -51.32% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -112.29% |
| Return on Equity (Trailing Twelve Months) | -72.56% |
| Return on Equity (5 Year) | -76.61% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -92.09% |
| Return on Investment (Trailing Twelve Months) | -63.77% |
| Return on Investment (5 Year) | -64.90% |